Candel Therapeutics (CADL) vs Prime Medicine (PRME)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Candel Therapeutics is the larger company by market cap ($751.4 million vs $707.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | CADL | PRME |
|---|---|---|
| Share price | $9.82 | $3.90 |
| Market cap | $751.41M | $707.37M |
| 1-day change | -0.51% | +11.43% |
| EPS (TTM) | $-1.46 | $-1.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.00 | $6.85 |
| 52-week low | $4.35 | $2.67 |
| Distance from 52-week high | -29.86% | -43.07% |
| Average volume | 1.23M | 3.32M |
| Shares outstanding | 76.52M | 181.38M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
CADL vs PRME FAQ
Which is bigger, Candel Therapeutics or Prime Medicine?
Candel Therapeutics (CADL) is larger, with a market capitalization of $751.41M compared with $707.37M for Prime Medicine (PRME).
Are Candel Therapeutics and Prime Medicine in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.